Antibody reduction is the spontaneous degradation of inter-chain disulfide bonds resulting in a build-up of partial related substances of an IgG in bioprocess streams. Join Aaron Martin, Associate Director of Analytical Development, for the live webinar on Tuesday, May 23, 2023 | 12pm EDT (US) | 11am CT (US).
Antibody Reduction in Bioprocessing
X-talk Read More »
Any current Good Manufacturing Practice (cGMP) E.coli program must be based on a solid strain development strategy. This thought led to the development of Cytovance’s Keystone Expression System to provide a robust, high-yield E.coli strain to support cGMP manufacturing of a biologic.
The number and variety of protein therapeutics have increased dramatically in recent years. To satisfy therapeutic demand, these molecules must be produced at large scale in mammalian or bacterial cell hosts; but with the greater variety in protein therapeutic molecules
Process Characterization & Statistical Modeling — Transforming Data into Knowledge Throughout the Product Lifecycle, Upcoming Webinar Hosted by Xtalks. It’s no surprise that data plays a pivotal role in the biopharmaceutical industry.
Oklahoma City, OK. – October 18, 2019 – Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate in the upcoming Recent Advances in Fermentation Technology (#RAFT) Conference to be held October 29 – November 1, 2017 at the Hyatt Coconut Point, Bonita Springs (Ft. Myers), Florida.
